Main info

Identifier:

HO902 NHL

Sponsor:

HOVON

Working group party:

Lymphoma

Age:

>= 18

Stage:

1st Line

Echelon:

Level D

Included patients:

250

(of 250)

Active sites:

55

(of 62)

Title:

A national study for blood based response monitoring of newly diagnosed aggressive B-cell lymphoma (DLBCL and HGBCL) patients

Timeline

Flow

Details

Phase:

Observational Prospective

Monitoring Type:

Objectives:

The primary objective is to obtain LB samples to develop a reliable blood based assay that identifies primary refractory and early relapsing patients, thus enabling clinical interventional trial in the near future.

The secondary objectives are to collect clinical data and pre-treatment tissue samples to allow for determining molecular profiles and to allow for correlation to the blood based assay.

Eligibility

Inclusion Criteria:

• Patients diagnosed with newly diagnosed DLBCL (including HGBCL-NOS and HGBCL-DH) according to WHO classification 2016
• Ann Arbor stage II-IV
• Patients intended to be treated with 6 cycles R-CHOP (or DA-EPOCH-R) as first-line treatment (successive inclusion in HOVON 151 or HOVON 152 is possible)
• Age ≥ 18 years

Exclusion Criteria:

• Patients with limited stage I,II disease planned to receive 3 cycles of R-CHOP + radiotherapy, or 4 x R-CHOP+ 2R

Registration Details

Participating Sites

= Active hospitals

= Inactive hospitals